S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:GMAB

Genmab A/S Stock Forecast, Price & News

$44.40
+0.28 (+0.63 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.10
Now: $44.40
$44.83
50-Day Range
$37.13
MA: $39.77
$44.12
52-Week Range
$16.24
Now: $44.40
$44.83
Volume1.28 million shs
Average Volume359,458 shs
Market Capitalization$29.10 billion
P/E Ratio34.42
Dividend YieldN/A
Beta0.93
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

MarketRank

Overall MarketRank

1.04 out of 5 stars

Medical Sector

839th out of 1,556 stocks

Pharmaceutical Preparations Industry

401st out of 638 stocks

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMAB
CUSIPN/A
CIKN/A
Phone45-7020-2728
Employees712

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$804.57 million
Cash Flow$0.55 per share
Book Value$3.24 per share

Profitability

Net Income$324.68 million

Miscellaneous

Market Cap$29.10 billion
Next Earnings Date2/17/2021 (Estimated)
OptionableNot Optionable
$44.40
+0.28 (+0.63 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genmab A/S (NASDAQ:GMAB) Frequently Asked Questions

How has Genmab A/S's stock price been impacted by Coronavirus (COVID-19)?

Genmab A/S's stock was trading at $20.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GMAB shares have increased by 115.5% and is now trading at $44.40.
View which stocks have been most impacted by COVID-19
.

Is Genmab A/S a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Genmab A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View analyst ratings for Genmab A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Genmab A/S?

Wall Street analysts have given Genmab A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genmab A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for Genmab A/S
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings data on Wednesday, November, 4th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. The business had revenue of $273.43 million for the quarter, compared to analysts' expectations of $232.86 million. Genmab A/S had a return on equity of 34.40% and a net margin of 50.99%.
View Genmab A/S's earnings history
.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.45225-1.54645 billion, compared to the consensus revenue estimate of $1.52 billion.

What price target have analysts set for GMAB?

13 Wall Street analysts have issued 12 month target prices for Genmab A/S's shares. Their forecasts range from $34.00 to $49.00. On average, they anticipate Genmab A/S's stock price to reach $41.00 in the next year. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Genmab A/S
or view Wall Street analyst' top-rated stocks.

Are investors shorting Genmab A/S?

Genmab A/S saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 594,700 shares, a decline of 21.2% from the December 15th total of 755,100 shares. Based on an average daily volume of 498,600 shares, the short-interest ratio is presently 1.2 days.
View Genmab A/S's Short Interest
.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), The Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 59)
  • Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 45)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 62)
  • Dr. Mijke Zachariasse Ph.D., Director of Protein Production & Chemistry and Non-Independent Director (Age 46)
  • Mr. Daniel J. Bruno, VP, Corp. Controller & Non-Independent Director (Age 40)
  • Mr. Anthony Pagano, Exec. VP & CFO (Age 42)
  • Mr. Anthony Mancini, Exec. VP & COO
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting
  • Ms. Marisol Mendez Peron, Head and Corp. VP of Communications & Investor Relations
  • Ms. Birgitte Stephensen M.Sc., Sr. VP of IPR & Legal (Age 59)

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

How do I buy shares of Genmab A/S?

Shares of GMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $44.40.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $29.10 billion and generates $804.57 million in revenue each year. The company earns $324.68 million in net income (profit) each year or $0.51 on an earnings per share basis. Genmab A/S employs 712 workers across the globe.

What is Genmab A/S's official website?

The official website for Genmab A/S is www.genmab.com.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.